The Glutamate Carboxypeptidase 2 pipeline drugs market research report outlays comprehensive information on the Glutamate Carboxypeptidase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Glutamate Carboxypeptidase 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Oncology, Undisclosed, and Gastrointestinal which include the indications Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostate Cancer, Unspecified, Ulcerative Colitis, and Crohn’s Disease (Regional Enteritis). It also reviews key players involved in Glutamate Carboxypeptidase 2 targeted therapeutics development with respective active and dormant or discontinued products.

The Glutamate Carboxypeptidase 2 pipeline targets constitutes close to 120 molecules. Out of which, approximately 88 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Phase 0, IND/ CTA Filed, Preclinical, and Discovery stages are 5, 18, 21, 3, 2, 31, and 8 respectively. Similarly, the universities portfolio in Phase II, Phase I, Phase 0, and Preclinical comprises 9, 10, 4, and 9 molecule.

Glutamate Carboxypeptidase 2 overview

Glutamate carboxypeptidase II (GCPII) is a membrane-bound binuclear zinc metallopeptidase with the highly expressed in nervous and prostatic tissue. Glutamate carboxypeptidase II (GCPII) is an enzyme encoded by the FOLH1 (folate hydrolase 1) gene. GCPII is intimately involved in the neuron-neuron and neuron-glia signaling via the hydrolysis of N-acetylaspartylglutamate (NAAG). The inhibition of the GCPII-controlled NAAG catabolism has been shown to plat important role in traumatic brain injury, stroke, neuropathic and inflammatory pain, amyotrophic lateral sclerosis, schizophrenia and prostate carcinoma.

For a complete picture of Glutamate Carboxypeptidase 2’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.